# In Vitro Synergistic Effects of Antibiotic Combinations Against Multidrug-Resistant Streptococcus suis from Diseased Pigs

**Authors:** Wiyada Chumpol, Kamonwan Lunha, Surasak Jiemsup, Suganya Yongkiettrakul

PMC · DOI: 10.3390/antibiotics15020136 · Antibiotics · 2026-01-29

## TL;DR

This study shows that combining certain antibiotics can effectively fight drug-resistant Streptococcus suis in pigs, offering a potential solution to antibiotic resistance.

## Contribution

The study identifies synergistic antibiotic combinations, particularly penicillin-gentamicin, as effective against multidrug-resistant S. suis in pigs.

## Key findings

- Penicillin-gentamicin showed synergistic activity against 52.6% of MDR S. suis strains.
- Time-kill assays confirmed rapid bacterial clearance with the penicillin-gentamicin combination.
- Combination therapy is proposed as a strategy to address antimicrobial resistance in S. suis.

## Abstract

Background/Objectives: Multidrug-resistant (MDR) strains of Streptococcus suis are increasingly prevalent and present significant challenges in clinical management. Given that the development of new antibiotics is a resource-intensive process and time-consuming, there is an urgent need for alternative therapeutic strategies to address resistance in the short term. One promising approach is the use of combination therapy, which involves pairing potent antibiotics with agents that may be less effective on their own, to enhance therapeutic efficacy and potentially overcome resistance mechanisms. This study aimed to investigate the in vitro antibacterial activity of combining two classes of antibiotics with distinct mechanisms of action—cell wall synthesis inhibitors and protein synthesis inhibitors—against MDR S. suis strains isolated from diseased pigs. Methods: A total of 36 MDR S. suis strains were tested using a microbroth dilution checkerboard assay to determine the minimum inhibitory concentration (MIC) of four cell wall synthesis inhibitors —amoxicillin/clavulanic acid (AMC), ampicillin (AMP), penicillin G (PEN), and vancomycin (VAN)— in combination with four protein synthesis inhibitors —gentamicin (GEN), neomycin (NEO), tilmicosin (TMS), and tylosin (TYL). Time–kill curve assays were conducted to evaluate the in vitro bactericidal activity of synergistic antibiotic combinations (PEN–GEN and AMP–NEO) against Beta-lactam-resistant and Beta-lactam-susceptible MDR S. suis strains. Results: Checkerboard analysis revealed that penicillin-gentamicin combination exhibited the most effective synergistic activity against the MDR S. suis strains (10/19, 52.6%), with ∑FIC values of 0.25–1.06 and MIC reductions from resistant to susceptible levels. Time-kill assays further confirmed the synergistic bactericidal effect of the combination, demonstrating complete bacterial clearance within 6–9 h, markedly rapid bacterial killing compared to monotherapy. Conclusions: This study demonstrates that antibiotic combinations, particularly Beta-lactams combined with aminoglycosides, show synergistic activity against pig-isolated S. suis MDR strains. The PEN-GEN combination exhibited strong synergistic and bactericidal effects, supporting combination therapy as a potential strategy to address antimicrobial resistance. Further evaluation in diverse strain backgrounds and prudent antibiotic use are essential to confirm efficacy and limit the emergence of antibiotic resistance.

## Linked entities

- **Chemicals:** amoxicillin/clavulanic acid (PubChem CID 6435924), ampicillin (PubChem CID 6249), penicillin G (PubChem CID 5904), vancomycin (PubChem CID 14969), gentamicin (PubChem CID 3467), neomycin (PubChem CID 8378), tilmicosin (PubChem CID 5282521), tylosin (PubChem CID 5280440)
- **Species:** Streptococcus suis (taxon 1307), Sus scrofa (taxon 9823)

## Full-text entities

- **Diseases:** pneumonia (MESH:D011014), streptococcal infections (MESH:D013290), injury to (MESH:D014947), meningitis (MESH:D008580), AMR (MESH:D060467), bacterial infections (MESH:D001424), endocarditis (MESH:D004696), septicemia (MESH:D018805), arthritis (MESH:D001168), S. suis infection (MESH:D007239)
- **Chemicals:** VAN (MESH:D014640), PEN (MESH:D010400), tetracyclines (MESH:D013754), TYL (MESH:D015645), tazobactam (MESH:D000078142), GEN (MESH:D005839), aminoglycoside (MESH:D000617), spectinomycin (MESH:D000198), AMC (MESH:D019980), sulfonamides (MESH:D013449), apramycin (MESH:C011666), AMP (MESH:D000667), clavulanic acid (MESH:D019818), CO2 (MESH:D002245), LEV (MESH:D007978), NEO (MESH:D009355), Beta-lactam (MESH:D047090), PEN (MESH:D010406), tetracycline (MESH:D013752), AMC-NEO (-), S (MESH:D013455), pleuromutilin (MESH:C004262), tiamulin (MESH:C014224), fluoroquinolones (MESH:D024841), cephalosporins (MESH:D002511), Macrolides (MESH:D018942), ceftriaxone (MESH:D002443), TMS (MESH:C052319)
- **Species:** Enterococcus faecalis (species) [taxon 1351], Streptococcus suis (species) [taxon 1307], Sus scrofa (pig, species) [taxon 9823], Streptococcus pneumoniae (species) [taxon 1313], Brachyspira hyodysenteriae (species) [taxon 159], Lawsonia intracellularis (species) [taxon 29546], Mycoplasma sp. (species) [taxon 2108], Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280], Actinobacillus pleuropneumoniae (species) [taxon 715]
- **Cell lines:** SS500 — Mus musculus (Mouse), Hybridoma (CVCL_A9NJ), SS394 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_8631)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937455/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937455/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937455/full.md

---
Source: https://tomesphere.com/paper/PMC12937455